21 Feb 2024 - {{hitsCtrl.values.hits}}
Covid vaccines from companies like Pfizer, Moderna and AstraZeneca were linked to rare occurrences of heart, brain and blood disorders, a recent peer-reviewed study found, though experts say the risks of developing Covid-19 greatly outweigh the risks of getting vaccinated.
The study, conducted by researchers from the Global Vaccine Data Network, a research arm of the World Health Organization (WHO), examined the rates of 13 medical conditions considered adverse events of special interest in a study population of 99 million vaccinated individuals across eight countries. This study marks the largest Covid vaccine study to date.
Among the notable findings, rare cases of myocarditis (inflammation of the heart) were identified following doses of Pfizer-BioNTech’s and Moderna’s mRNA vaccines. The study reported the highest rate of myocarditis after the second dose of Moderna’s vaccine, with a 6.1-fold increased risk compared to the expected rate of cases.
Additionally, pericarditis, another heart condition, showed a 6.9-fold increased risk in those who received a third dose of AstraZeneca’s viral-vector vaccine, as well as increased risks associated with certain doses of Moderna’s vaccine.
Furthermore, the study revealed increased risks of developing the rare autoimmune disorder Guillain-Barre syndrome and blood clots among those who received AstraZeneca’s vaccine. Similarly, there were increased risks of neurological disorders, such as acute disseminated encephalomyelitis, following vaccination with Moderna’s and AstraZeneca’s vaccines.
It is worth noting that despite these findings, experts emphasize that the risks of developing Covid-19 greatly outweigh the risks associated with vaccination.
Approximately 71% of the world’s population has received at least one dose of a Covid vaccine, highlighting the global effort to mitigate the spread and impact of the virus.
07 Nov 2024 34 minute ago
07 Nov 2024 46 minute ago
07 Nov 2024 1 hours ago
07 Nov 2024 3 hours ago
07 Nov 2024 4 hours ago